Comparison of mean HbA1c with sitagliptin plus metformin versus glimepride plus metformin for the management of uncontrolled type 2 diabetes mellitus

Aim: to compare the mean hba1c with sitagliptin plus metformin versus glimepiride plus metformin for management of cases presenting due to uncontrolled type 2 diabetes mellitus. methods: this was a research randomized control trial that was planned and executed at department of medicine,mayo hospital lahore for 6 months (date: 1st june 2016 to 31st november).the non-probability purposive sampling was used. all patients were randomly divided in two equal groups by using lottery method. blood sample was obtained and was sent to laboratory of hospital for assessment of baseline hba1c. patients in s group were given sitagliptin and patients in g group were given glimepiride. initially patients were given dose of 50/100mg per day sitagliptinand of1/2 mg per day glimepiride. dose of metformin was not changed throughout research. results: the mean age of the patients was 57.36±11.91 years,the male to female ratio of the patients was 1.7: 1. the mean hba1c baseline was 8.30±0.72 and the mean hba1c at 12th week was 6.39±1.13. the mean hba1c at 12 week in sitagliptin group was 5.39±0.45 and meanhba1c in glimepiride group was 7.38±0.61. significant difference was found between the study groups and hba1c at 12th week i.e. p-value=0.000. conclusion: it has been proved by our study that at 12th week significant lower mean value of hba1c with sitagliptin plus metformin was found as compared to glimepiride plus metformin for controlling the level of diabetes mellitus in the cases of uncontrolled type 2 diabetes mellitus.